Holt 2021 — Dual AAV STRC Delivery (Science Advances)
Journal: Science Advances, December 2021
PMID: 34910522
PMC: PMC8673757
Lab: Jeffrey Holt, Boston Children’s Hospital / Harvard Medical School
Key Ideas
- P1 neonatal intracochlear injection of dual-AAV STRC cDNA. Timing matters: P1 is before OHC maturation, maximizing transduction window.
- ABR threshold rescue of 50-60 dB across frequencies. DPOAE amplitudes also restored.
- OHC stereocilia bundle morphology restored in 59-65% of cells — close to the 60% Iranfar 2026 also reports independently.
- Key author quote: “STRC mutations did not cause early hair cell death, unlike other hearing loss mutations.” This is the mechanistic argument for why treatment can work even after early life: the cells are still alive.
- This work became the scientific basis for Regeneron’s AAV.104 program, acquired from Decibel Therapeutics in 2023 for $109M.
- Holt stated 4-6 year timeline to human trials in 2022. First-in-human realistically 2026-2028.
My Thoughts
The OHC survival observation is load-bearing for Misha’s case. DFNB16 is not a hair cell death disease in the way DFNB9 (OTOF) or some syndromes are. The cells are structurally intact — they just lack the tip link accessory protein. That means the treatment window is longer than typical deafness conditions, and Misha’s existing hair cells at age 4 are almost certainly alive and addressable.
The $109M Decibel acquisition and Regeneron AAV.104 program make this the commercial-track path to watch. Regeneron has the manufacturing scale, regulatory experience (post-CHORD DB-OTO), and financial motivation to push this forward faster than an academic lab could.
The 4-6 year timeline from 2022 puts first-in-human at 2026-2028 — Misha is 4 now. If AAV.104 phases are standard, pediatric expansion comes after adult first-in-human (or the CHORD OTOF data may argue for direct pediatric inclusion, given DB-OTO’s 10-month-to-16-year age range). Realistic Misha access: 2029-2032 if everything goes well.
Connections
[supports]STRC Mini-STRC Single-Vector Hypothesis — Holt’s dual-AAV STRC work is the direct predecessor Regeneron acquired[part-of]STRC Gene Therapy Landscape 2026[about]Misha[about]Jeffrey Holt[see-also]2026-01-iranfar-dual-aav-strc-ctm- Adult Treatment Window STRC — Holt’s OHC survival observation directly informs this